"We are very pleased to receive this third patent for our anti-PE program, which adds to our leadership in the emerging field of aminophospholipid-targeting anti-viral agents," said Shelley Fussey, Ph.D., vice president of intellectual property at Peregrine. "This latest patent is the direct result of our ongoing research collaboration with leading researchers at UT Southwestern Medical Center who have been instrumental in establishing our position at the forefront of developing therapeutic agents that target phospholipids."
U.S. Patent #7,511,124, which issued on March 31, 2009, was granted to the
1. M. Melina Soares, Susan Mims, Gustavo Barbero, Shuzhen Li and Philip E. Thorpe, "Anti-Viral Effects of Phosphatidylethanolamine-Targeting Agents", American Association of Immunologists Annual Meeting, San Diego, California, April 7, 2008.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside custo
|SOURCE Peregrine Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved